

Recombinant Human VEGFR3/FLT4 Protein (His Tag)

Catalog No. PKSH031419

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	FLT-4;FLT-41;FLT41;LMPH1A;PCL;VEGF Receptor 3;VEGFR-3;VEGFR3
Species	Human
Expression Host	HEK293 Cells
Sequence	Met 1-Ile 776
Accession	NP_002011.2
Calculated Molecular Weight	86.0 kDa
Observed molecular weight	130 kDa
Tag	C-His
Bioactivity	Measured by its binding ability in a functional ELISA. Immobilized human VEGF-C at 10 µg/mL (100 µl/well) can bind human VEGFR3-his. The EC50 of human VEGFR3-his is 0.011 µg/mL. Measured by its ability to bind human VEGF-D in a functional ELISA.

Properties

Purity	> 97 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 97 % as determined by reducing SDS-PAGE.

For Research Use Only

Background

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

For Research Use Only